Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
about
Perspectives in Intraoperative Diagnostics of Human GliomasMultimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR ImagingPhase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.Clinical utility of 5-aminolevulinic acid HCl to better visualize and more completely remove gliomas.The comprehensive neuro-oncology data repository (CONDR): a research infrastructure to develop and validate imaging biomarkersMeningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO reviewResponse assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic Acid-guided surgery.Factors associated with a higher rate of distant failure after primary treatment for glioblastoma.Surgical management of high-grade glioma: a standard of care.What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?Subventricular zones: new key targets for glioblastoma treatment.A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.Analysis of heterogeneity in T2-weighted MR images can differentiate pseudoprogression from progression in glioblastoma.Intraoperative magnetic resonance imaging versus standard neuronavigation for the neurosurgical treatment of glioblastoma: A randomized controlled trialMetabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide TreatmentSurgical resection of malignant gliomas-role in optimizing patient outcome.Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomasIdentifying the association of contrast enhancement with vascular endothelia growth factor expression in anaplastic gliomas: a volumetric magnetic resonance imaging analysisImaging of gliomas at 1.5 and 3 Tesla - A comparative study.Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma.CNS Anticancer Drug Discovery and Development Conference White Paper.Simultaneous 11C-Methionine Positron Emission Tomography/Magnetic Resonance Imaging of Suspected Primary Brain Tumors.Outcomes after combined use of intraoperative MRI and 5-aminolevulinic acid in high-grade glioma surgeryLong-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.Correlation between contrast enhancement on intraoperative magnetic resonance imaging and histopathology in glioblastomaSemi-Automated Volumetric and Morphological Assessment of Glioblastoma Resection with Fluorescence-Guided SurgeryVisualization of heterogeneity and regional grading of gliomas by multiple features using magnetic resonance-based clustered images.Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysisMultimodal MRI can identify perfusion and metabolic changes in the invasive margin of glioblastomas.Glioma virus therapies between bench and bedside.Pseudoprogression and pseudoresponse in the management of high-grade glioma : optimal decision timing according to the response assessment of the neuro-oncology working group.Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status5-Aminolevulinic acid fluorescence in high grade glioma surgery: surgical outcome, intraoperative findings, and fluorescence patterns5-aminolevulinic acid (5-ALA) fluorescence guided surgery of high-grade gliomas in eloquent areas assisted by functional mapping. Our experience and review of the literature.Bevacizumab for the treatment of glioblastoma.Public disclosure of surgeon's results--pituitary surgery.The evolving role of neurological imaging in neuro-oncology.The role of surgery in grade II/III oligodendroglial tumors.
P2860
Q26778788-B4E14572-E98A-4289-B8A0-33953CDD0DC8Q26796223-025BA287-FD8E-43E6-8ACC-0EE94FDD2CDAQ27310843-CFD25B5A-CE69-4599-A1F9-68E9B106A857Q28078505-78CDCE8F-93CB-41D0-AE36-5C260D90FB3EQ28608269-86D37855-F195-429D-8F56-3D04D584C780Q30356126-C2B9B0CF-2CCA-4D72-BD52-818594FE11ADQ30607148-901067C7-DF94-48D4-96A6-2FB611F72808Q30628099-ECA1EA82-A185-40AC-87DE-9BFF8462F74AQ30679537-70D2C749-1E11-4CF3-83A0-9070C3BD2BF6Q30838365-29C4F650-8942-4EF5-B765-4CECA8CE4452Q30989894-7854DF3A-CF76-4689-BB66-C5478CD901F6Q33582057-98517F62-49E6-4094-9D6B-4F2C383BCA50Q33587028-CFA07340-628A-4C44-B954-7EBA7C803B64Q33698886-4A0E4799-054F-4677-86D4-7A0D696E8C6BQ33833522-D7328060-85D6-4C49-9DFA-AD42FE0691A6Q33844943-CC14D29C-6AE9-4994-A261-1AB7E8E62F28Q34324963-D1B1C4DF-4942-46E0-90EC-FD5BB74C1425Q34331320-04E16FC5-92FA-4F3C-BF37-F8FE2D1203D8Q34414528-3561452A-9110-4A5E-9FED-2C608E2DFBEDQ35231324-B76D944C-BA0A-469A-AD31-AA15CD561F90Q35788981-66E59287-8310-429F-95D0-7207AA185F6EQ36054267-E7EC71EB-C761-409F-B674-A0DAF85015B8Q36089590-9D3C79CE-3F67-4934-9A3C-F5EB90D8F9B5Q36210293-DC9F6D68-3DCD-4C8E-8627-6E8E4933E7A7Q36250718-29F2982F-4924-4534-9AC1-F642F01A70E3Q36250744-74BB71C8-7FB2-4E10-A80E-C4DB8D267E9EQ36551711-8EA95A6F-5D7C-47A1-9A87-9CD9D4512A02Q36889298-F896505A-97FA-47E8-BA21-AF6E999439B1Q37125317-B2CF1977-F8D7-4080-BE78-784F2DD41DD0Q37191509-B3447AF9-8995-40D5-8003-6E3142A6433BQ37225057-B2FA3C78-6DA3-4821-82E5-E29C053FAD6EQ37580510-C161D1E8-292A-49B1-BA79-16B1802FF0E4Q37591724-DDB76040-3105-4A32-A13D-B7994EB551C1Q37677994-B3EFBF22-F357-4C13-A69B-C0C26EFAD6F3Q37720272-744EE140-4556-409F-8DE3-7A52081DF3D6Q38087262-27066406-3B1A-4387-87D6-4DB941F493AFQ38129428-28E83900-8340-4ABA-8539-B34C32A99482Q38151160-C62A4663-F829-4308-9AF1-83F883C0065BQ38235857-F9C74380-1371-4222-AD24-A9B7AD7905E3Q38610485-27CD3DB4-4C7D-435D-AB76-62AAFA9435F3
P2860
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Application of novel response/ ...... Oncology (RANO) Working Group.
@ast
Application of novel response/ ...... Oncology (RANO) Working Group.
@en
type
label
Application of novel response/ ...... Oncology (RANO) Working Group.
@ast
Application of novel response/ ...... Oncology (RANO) Working Group.
@en
prefLabel
Application of novel response/ ...... Oncology (RANO) Working Group.
@ast
Application of novel response/ ...... Oncology (RANO) Working Group.
@en
P2093
P2860
P1433
P1476
Application of novel response/ ...... Oncology (RANO) Working Group.
@en
P2093
Amy B Heimberger
David R Macdonald
John H Sampson
Manish K Aghi
Martin J Van den Bent
Michael A Vogelbaum
Patrick Y Wen
Sarah Jost
Susan M Chang
P2860
P304
234-43; discussion 243-4
P356
10.1227/NEU.0B013E318223F5A7
P407
P577
2012-01-01T00:00:00Z